FINDINGS
Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. These engineered cells not only destroyed the infected cells, they persisted for more than two years, suggesting the potential to create long-term immunity from the virus that causes AIDS.
BACKGROUND
Antiviral drugs can suppress the amount of HIV in the body to nearly undetectable levels, but only an effective immune response can eradicate the virus. Researchers have been seeking a way to improve the body’s ability to combat the virus by engineering blood-forming stem cells to specifically target and kill HIV-infected cells for the life of the individual. Although chimeric antigen receptor (CAR) T-cells have emerged as a powerful immunotherapy for various forms of cancer – and show promise in treating HIV-1 infection – the therapy may not impart long-lasting immunity. Researchers, physicians and patients need T cell-based products that can respond to malignant or infected cells that may reappear months or years after treatment.
METHOD
Because HIV uses CD4 to infect cells, the researchers used a CAR molecule that hijacks the essential interaction between HIV and the cell surface molecule CD4 to make stem cell-derived T-cells target infected cells. When the CD4 on the CAR molecule binds to HIV, other regions of the CAR molecule signal the cell to become activated and kill the HIV infected cell. The researchers found that, in test animals, modification of the blood-forming stem cells resulted in more than two years of stable production of CAR-expressing cells without any adverse effects. In addition, these cells were widely distributed throughout the lymphoid tissues and gastrointestinal tract, which are major anatomic sites for HIV replication and persistence in infected people. Most important, engineered CAR T-cells showed efficacy in attacking and killing HIV-infected cells.
IMPACT
These findings are the first to show that blood-forming stem cells can be modified with a CAR therapy that can safely engraft in the bone marrow, mature and become functional immune cells throughout the body. This could lead to the development of an approach allowing for safe, lifelong immunity to HIV. Such an approach is likely to work best when performed in combination with other treatment strategies, such as antiretroviral therapy. Researchers hope that this type of therapy could reduce infected individuals’ dependence on antiviral medications, lower the cost of therapy, and permit the possible eradication of HIV from its hiding places in the body. The approach also has potential against other infections or malignancies.
Learn more: Gene Therapy Using CAR T-Cells Could Provide Long-Term Protection Against HIV
The Latest on: HIV gene therapy
[google_news title=”” keyword=”HIV gene therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- How Gene Editing Therapies Could Go Beyond Rare Diseaseson May 16, 2024 at 6:00 am
In the wake of the first CRISPR medicine, scientists are working to develop gene editing therapies for diseases like cystic fibrosis, ALS and cardiovascular disease.
- A Gene Editing Treatment That Takes Aim at Herpes Infectionson May 14, 2024 at 8:50 am
It's estimated that about 3.7 billion people under the age of 50 are infected with (HSV-1), which can cause oral herpes. | Cell And Molecular Biology ...
- CRISPR gene therapy EBT-101 does not prevent HIV viral reboundon May 13, 2024 at 5:00 pm
£35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts. A CRISPR-based gene-editing therapy called EBT-101 was safe and well ...
- Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Studyon May 13, 2024 at 8:32 am
Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, Excision BioTherapeutics’ HIV gene editor failed to suppress viral activity.
- Excision BioTherapeutics Announces Data from the Phase 1/2 Trial of EBT-101 in HIV And In Vivo Efficacy Data in Herpes Virus and Hepatitis Bon May 13, 2024 at 5:56 am
EBT-101 successfully met the primary endpoint of safety and secondary endpoint of biodistribution/immunogenicity in a Phase 1/2 study ...
- We now know Tome’s gene editing targeton May 13, 2024 at 5:41 am
Initially to treat a rare disease called phenylketonuria —To design a natural killer cell therapy heavily engineered to safely treat autoimmune diseases ...
- Study highlights need for cell-type-specific therapies in treatment of HIVon May 13, 2024 at 5:33 am
Researchers from the University of Illinois have demonstrated the importance of cell-type-specific targeting in the treatment of HIV. Their study, published in the Proceedings of the National Academy ...
- Proposed Medicaid rule may hurt people with HIVon May 11, 2024 at 12:34 pm
This could mean trouble for drugs whose largest market is Medicaid, like those that treat HIV. If manufacturers and their investors decide that it’s no longer financially viable to make drugs that ...
- Can HIV be cured using gene editing? We will soon find outon May 10, 2024 at 7:30 am
We will have to wait till 2024 for the first report on efficacy. Despite the availability of antiretroviral drugs, hundreds of thousands of people still die from Aids each year. A cure for the disease ...
- Q&A: Scientist partners with colleagues around the globe to make gene therapies more effective and widely availableon May 9, 2024 at 2:00 pm
Fred Hutch Cancer Center scientist Jennifer E. Adair, Ph.D., is on a mission to foster worldwide collaboration on potentially curative gene therapies.
via Google News and Bing News